A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.
Investigators from the laboratory of Ali Shilatifard, PhD, have developed a novel technique to precisely and efficiently study gene regulation, which may accelerate the development of new therapeutic strategies, according to a recent study published in Molecular Cell.
Scientists have uncovered new insights into the molecular players behind calcium channel regulation, a biological process that coordinates a wide array of physiological responses, according to a study published in the Proceedings of the National Academy of Sciences.
The use of active surveillance and watchful waiting increased from 13.2 percent in 2010 to 53.8 percent in 2020 among patients with intermediate-risk prostate cancer, according to a recent study published in JAMA.
Northwestern Medicine scientists have developed a method for identifying reactive cysteines on peptide antigens within the immune system, a development which may prove useful in cancer immunotherapy, according to a study published in Nature Communications.
A new blood test may help reduce unnecessary prostate biopsies and can detect prostate cancer with similar sensitivity to standard screening in patients across racial and ethnic groups, according to a recent study published in the Journal of Clinical Oncology.
Northwestern Medicine investigators have discovered new molecular mechanisms underlying DNA repair dysregulation in cancer cells, findings that may inform the development of new targeted therapies for patients that have become resistant to standard treatments.
Acceptance and commitment therapy significantly decreased fatigue interference and improved quality of life in patients with metastatic breast cancer six months after treatment, according to recent findings published in the Journal of Clinical Oncology.
Patients with a subtype of glioblastoma who received a combination treatment of a PARP inhibitor and standard chemotherapy did not demonstrate improved survival compared to chemotherapy and placebo, according to a recent clinical trial published in JAMA Oncology.
A type of immunotherapy appears to be effective in treating a deadly subset of thyroid cancer, according to the results of a clinical trial published in JAMA Oncology.